Vaxart ( (VXRT) ) has released its Q4 earnings. Here is a breakdown of the information Vaxart presented to its investors.
Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary pill-based delivery platform, targeting diseases such as coronavirus, norovirus, and influenza. In its latest earnings report, Vaxart highlighted the initiation of a Phase 1 clinical trial for its second-generation oral norovirus vaccine, with results expected by mid-2025. The company also continues to monitor its COVID-19 vaccine trial and advances its avian influenza program. Financially, Vaxart reported a net loss of $66.9 million for 2024, an improvement from the previous year, with revenue increasing significantly to $28.7 million primarily due to government contracts. Looking ahead, Vaxart remains focused on advancing its vaccine candidates through clinical trials and achieving key development milestones, supported by its current cash reserves projected to last into late 2025.